BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Švajger U, Rožman PJ. Recent discoveries in dendritic cell tolerance-inducing pharmacological molecules. Int Immunopharmacol 2020;81:106275. [PMID: 32044665 DOI: 10.1016/j.intimp.2020.106275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Li H, Yang Y, Sun T. Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases. Front Bioeng Biotechnol 2022;10:889291. [DOI: 10.3389/fbioe.2022.889291] [Reference Citation Analysis]
2 Nagy NA, de Haas AM, Geijtenbeek TBH, van Ree R, Tas SW, van Kooyk Y, de Jong EC. Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance. Front Immunol 2021;12:674048. [PMID: 34054859 DOI: 10.3389/fimmu.2021.674048] [Reference Citation Analysis]
3 van Wigcheren GF, Roelofs D, Figdor CG, Flórez-Grau G. Three distinct tolerogenic CD14+ myeloid cell types to actively manage autoimmune disease: Opportunities and challenges. J Autoimmun 2021;120:102645. [PMID: 33901801 DOI: 10.1016/j.jaut.2021.102645] [Reference Citation Analysis]
4 Tabares-Guevara JH, Jaramillo JC, Ospina-Quintero L, Piedrahíta-Ochoa CA, García-Valencia N, Bautista-Erazo DE, Caro-Gómez E, Covián C, Retamal-Díaz A, Duarte LF, González PA, Bueno SM, Riedel CA, Kalergis AM, Ramírez-Pineda JR. IL-10-Dependent Amelioration of Chronic Inflammatory Disease by Microdose Subcutaneous Delivery of a Prototypic Immunoregulatory Small Molecule. Front Immunol 2021;12:708955. [PMID: 34305950 DOI: 10.3389/fimmu.2021.708955] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Benito-Villalvilla C, Pérez-Diego M, Angelina A, Kisand K, Rebane A, Subiza JL, Palomares O. Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring. J Allergy Clin Immunol 2021:S0091-6749(21)00968-4. [PMID: 34153371 DOI: 10.1016/j.jaci.2021.06.012] [Reference Citation Analysis]
6 Machcińska M, Kotur M, Jankowska A, Maruszewska-Cheruiyot M, Łaski A, Kotkowska Z, Bocian K, Korczak-Kowalska G. Cyclosporine A, in Contrast to Rapamycin, Affects the Ability of Dendritic Cells to Induce Immune Tolerance Mechanisms. Arch Immunol Ther Exp (Warsz) 2021;69:27. [PMID: 34632525 DOI: 10.1007/s00005-021-00632-7] [Reference Citation Analysis]
7 Morante-Palacios O, Fondelli F, Ballestar E, Martínez-Cáceres EM. Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases. Trends Immunol 2021;42:59-75. [PMID: 33293219 DOI: 10.1016/j.it.2020.11.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
8 Herrmann N, Nümm TJ, Iwamoto K, Leib N, Koch S, Majlesain Y, Maintz L, Kirins H, Schnautz S, Bieber T. Vitamin D3-Induced Promotor Dissociation of PU.1 and YY1 Results in FcεRI Reduction on Dendritic Cells in Atopic Dermatitis. J Immunol 2021;206:531-9. [PMID: 33443066 DOI: 10.4049/jimmunol.2000667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Passeri L, Marta F, Bassi V, Gregori S. Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity. Int J Mol Sci 2021;22:8415. [PMID: 34445143 DOI: 10.3390/ijms22168415] [Reference Citation Analysis]
10 Ríos-Ríos WJ, Sosa-Luis SA, Torres-Aguilar H. Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes. World J Diabetes 2021; 12(5): 603-615 [PMID: 33995848 DOI: 10.4239/wjd.v12.i5.603] [Reference Citation Analysis]